A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.
- Citation:
- J Clin Oncol vol 30 (suppl) abstr 6526
- Meeting Instance:
- ASCO 2012
- Year:
- 2012
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 748
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- E. C. Attar J. L. Johnson P. C. Amrein G. Lozanski M. Wadleigh D. J. Deangelo J. E. Kolitz B. L. Powell P. M. Voorhees E. S. Wang W. G. Blum G. Marcucci C. D. Bloomfield B. K. Moser R. M. Stone R. A. Larson
- Networks:
- Study
- CALGB-10502
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: